Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle D Nezolosky

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
International Journal of Radiation Oncology, Biology, Physics|August 7, 2016
Association Between Travel Distance and Choice of Treatment for Prostate Cancer: Does Geography Reduce Patient Choice?Vinayak Muralidhar, Brent S Rose, Yu-Wei Chen, et al.
Clinical Genitourinary Cancer|June 30, 2015
Association Between Older Age and Increasing Gleason ScoreVinayak Muralidhar, David R Ziehr, Brandon A Mahal, et al.
The Prostate|July 14, 2020
Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial prioritiesEdward Christopher Dee, Michelle D Nezolosky, Fallon E Chipidza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2016
Association of Androgen Deprivation Therapy With Depression in Localized Prostate CancerKathryn T Dinh, Gally Reznor, Vinayak Muralidhar, et al.
Urologic Oncology|October 19, 2015
Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012Michelle D Nezolosky, Kathryn T Dinh, Vinayak Muralidhar, et al.
Brachytherapy|April 19, 2015
Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancerVinayak Muralidhar, Brandon A Mahal, David R Ziehr, et al.
Urology|September 23, 2015
Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?Kathryn T Dinh, Vinayak Muralidhar, Brandon A Mahal, et al.
Clinical Genitourinary Cancer|December 3, 2017
Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active SurveillanceDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Cancer|August 24, 2017
Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Urologic Oncology|May 21, 2015
Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imagingVinayak Muralidhar, Kathryn T Dinh, Brandon A Mahal, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
International Journal of Radiation Oncology, Biology, Physics|August 7, 2016
Association Between Travel Distance and Choice of Treatment for Prostate Cancer: Does Geography Reduce Patient Choice?Vinayak Muralidhar, Brent S Rose, Yu-Wei Chen, et al.
Clinical Genitourinary Cancer|June 30, 2015
Association Between Older Age and Increasing Gleason ScoreVinayak Muralidhar, David R Ziehr, Brandon A Mahal, et al.
The Prostate|July 14, 2020
Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial prioritiesEdward Christopher Dee, Michelle D Nezolosky, Fallon E Chipidza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2016
Association of Androgen Deprivation Therapy With Depression in Localized Prostate CancerKathryn T Dinh, Gally Reznor, Vinayak Muralidhar, et al.
Urologic Oncology|October 19, 2015
Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012Michelle D Nezolosky, Kathryn T Dinh, Vinayak Muralidhar, et al.
Brachytherapy|April 19, 2015
Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancerVinayak Muralidhar, Brandon A Mahal, David R Ziehr, et al.
Urology|September 23, 2015
Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?Kathryn T Dinh, Vinayak Muralidhar, Brandon A Mahal, et al.
Clinical Genitourinary Cancer|December 3, 2017
Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active SurveillanceDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Cancer|August 24, 2017
Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Urologic Oncology|May 21, 2015
Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imagingVinayak Muralidhar, Kathryn T Dinh, Brandon A Mahal, et al.
Pageof 2